{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:25:35Z","timestamp":1783772735680,"version":"3.55.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T00:00:00Z","timestamp":1494201600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T00:00:00Z","timestamp":1494201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1111\/bjd.15155","type":"journal-article","created":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T08:33:39Z","timestamp":1494232419000},"page":"1465-1474","source":"Crossref","is-referenced-by-count":67,"title":["DOMINO, doxycycline 40\u00a0mg vs. minocycline 100\u00a0mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety"],"prefix":"10.1093","volume":"176","author":[{"given":"M.M.D.","family":"van der Linden","sequence":"first","affiliation":[{"name":"Department of Dermatology; Academic Medical Centre; University of Amsterdam; Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"van Ratingen","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Academic Medical Centre; University of Amsterdam; Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.C.","family":"van Rappard","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Academic Medical Centre; University of Amsterdam; Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Nieuwenburg","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Academic Medical Centre; University of Amsterdam; Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ph.I.","family":"Spuls","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Academic Medical Centre; University of Amsterdam; Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,5,8]]},"reference":[{"key":"10.1111\/bjd.15155-BIB0001|bjd15155-cit-0001","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jaad.2013.04.043","article-title":"Rosacea: current state of epidemiology","volume":"69","author":"Tan","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15155-BIB0002|bjd15155-cit-0002","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1468-3083.2009.03472.x","article-title":"Risk factors associated with rosacea","volume":"24","author":"Abram","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.15155-BIB0003|bjd15155-cit-0003","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamadermatol.2015.2230","article-title":"Genetic versus environmental factors that correlate with rosacea: a cohort-based survey of twins","volume":"151","author":"Aldrich","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1111\/bjd.15155-BIB0004|bjd15155-cit-0004","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/jidsymp.2011.7","article-title":"Clinical, cellular, and molecular aspects in the pathophysiology of rosacea","volume":"15","author":"Steinhoff","year":"2011","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1111\/bjd.15155-BIB0005|bjd15155-cit-0005","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2009.04.007","article-title":"The molecular pathology of rosacea","volume":"55","author":"Yamasaki","year":"2009","journal-title":"J Dermatol Sci"},{"key":"10.1111\/bjd.15155-BIB0006|bjd15155-cit-0006","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/jidsymp.2011.6","article-title":"Neurovascular and neuroimmune aspects in the pathophysiology of rosacea","volume":"15","author":"Schwab","year":"2011","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1111\/bjd.15155-BIB0007|bjd15155-cit-0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jidsymp.2011.3","article-title":"Pathophysiology of rosacea: introduction","volume":"15","author":"Steinhoff","year":"2011","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1111\/bjd.15155-BIB0008|bjd15155-cit-0008","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/jidsymp.2011.4","article-title":"Rosacea as a disease of cathelicidins and skin innate immunity","volume":"15","author":"Yamasaki","year":"2011","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1111\/bjd.15155-BIB0009|bjd15155-cit-0009","first-page":"694","article-title":"Why is rosacea considered to be an inflammatory disorder? The primary role, clinical relevance, and therapeutic correlations of abnormal innate immune response in rosacea-prone skin","volume":"11","author":"Del Rosso","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.15155-BIB0010|bjd15155-cit-0010","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jaad.2013.04.045","article-title":"New insights into rosacea pathophysiology: a review of recent findings","volume":"69","author":"Steinhoff","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15155-BIB0011|bjd15155-cit-0011","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/11530200-000000000-00000","article-title":"The role of tetracyclines in rosacea","volume":"11","author":"Alikhan","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"10.1111\/bjd.15155-BIB0012|bjd15155-cit-0012","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000235550","article-title":"Tetracycline actions relevant to rosacea treatment","volume":"22","author":"Korting","year":"2009","journal-title":"Skin Pharmacol Physiol"},{"key":"10.1111\/bjd.15155-BIB0013|bjd15155-cit-0013","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/ajd.12075","article-title":"Non-antibiotic properties of tetracyclines and their clinical application in dermatology","volume":"55","author":"Perret","year":"2014","journal-title":"Australas J Dermatol"},{"key":"10.1111\/bjd.15155-BIB0014|bjd15155-cit-0014","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1471-4159.2005.03219.x","article-title":"Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity","volume":"94","author":"Kraus","year":"2005","journal-title":"J Neurochem"},{"key":"10.1111\/bjd.15155-BIB0015|bjd15155-cit-0015","first-page":"16","article-title":"Effectiveness and safety of doxycycline 40\u00a0mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial","volume":"86","author":"Del Rosso","year":"2010","journal-title":"Cutis"},{"key":"10.1111\/bjd.15155-BIB0016|bjd15155-cit-0016","first-page":"4","article-title":"The ORCA (Oracea for rosacea: a community-based assessment) trial: a large-scale, phase 4 trial in papulopustular rosacea","volume":"86","author":"Del Rosso","year":"2010","journal-title":"Cutis"},{"key":"10.1111\/bjd.15155-BIB0017|bjd15155-cit-0017","first-page":"573","article-title":"Comparison of anti-inflammatory dose doxycycline versus doxycycline 100\u00a0mg in the treatment of rosacea","volume":"7","author":"Del Rosso","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.15155-BIB0018|bjd15155-cit-0018","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaad.2006.11.021","article-title":"Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea","volume":"56","author":"Del Rosso","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15155-BIB0019|bjd15155-cit-0019","first-page":"641","article-title":"Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea","volume":"6","author":"Fowler","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.15155-BIB0020|bjd15155-cit-0020","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaad.2005.04.069","article-title":"A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea","volume":"53","author":"Sanchez","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15155-BIB0021|bjd15155-cit-0021","first-page":"292","article-title":"Efficacy of extended-release 45\u00a0mg oral minocycline and extended-release 45\u00a0mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea","volume":"12","author":"Jackson","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.15155-BIB0022|bjd15155-cit-0022","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1365-2133.1975.tb02252.x","article-title":"A follow-up of tetracycline-treated rosacea. With special reference to rosacea keratitis","volume":"93","author":"Knight","year":"1975","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15155-BIB0023|bjd15155-cit-0023","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/1346-8138.13166","article-title":"Prognosis of 234 rosacea patients according to clinical subtype: the significance of central facial erythema in the prognosis of rosacea","volume":"43","author":"Lee","year":"2016","journal-title":"J Dermatol"},{"key":"10.1111\/bjd.15155-BIB0024|bjd15155-cit-0024","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.12385","article-title":"An observational cross-sectional survey of rosacea: clinical associations and progression between subtypes","volume":"169","author":"Tan","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15155-BIB0025|bjd15155-cit-0025","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1046\/j.1365-4362.2003.01780.x","article-title":"Measuring the severity of rosacea: a review","volume":"42","author":"Gessert","year":"2003","journal-title":"Int J Dermatol"},{"key":"10.1111\/bjd.15155-BIB0026|bjd15155-cit-0026","first-page":"687","article-title":"[Rilmenidine in rosacea: a double-blind study versus placebo]","volume":"124","author":"Grosshans","year":"1997","journal-title":"Ann Dermatol Venereol"},{"key":"10.1111\/bjd.15155-BIB0027|bjd15155-cit-0027","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaad.2007.01.048","article-title":"A pilot quality-of-life instrument for acne rosacea","volume":"57","author":"Nicholson","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15155-BIB0028|bjd15155-cit-0028","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0895-4356(96)00373-3","article-title":"A comparison of different indices of responsiveness","volume":"50","author":"Wright","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1111\/bjd.15155-BIB0029|bjd15155-cit-0029","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/0895-4356(93)90142-N","article-title":"Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines","volume":"46","author":"Guillemin","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"10.1111\/bjd.15155-BIB0030|bjd15155-cit-0030","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1001\/archderm.139.11.1444","article-title":"A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial","volume":"139","author":"Elewski","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.15155-BIB0031|bjd15155-cit-0031","first-page":"1380","article-title":"Long-term safety of ivermectin 1% cream versus azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials","volume":"13","author":"Stein","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.15155-BIB0032|bjd15155-cit-0032","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.13408","article-title":"Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial","volume":"172","author":"Taieb","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15155-BIB0033|bjd15155-cit-0033","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archderm.134.6.679","article-title":"Topical metronidazole maintains remissions of rosacea","volume":"134","author":"Dahl","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.15155-BIB0034|bjd15155-cit-0034","first-page":"639","article-title":"A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy","volume":"8","author":"Thiboutot","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.15155-BIB0035|bjd15155-cit-0035","unstructured":"U.S. Food and Drug Administration What is a serious adverse event? http:\/\/www.fda.gov\/safety\/medwatch\/howtoreport\/ucm053087.htm"},{"key":"10.1111\/bjd.15155-BIB0036|bjd15155-cit-0036","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.jaad.2009.08.020","article-title":"A pilot study in discrepancies in quality of life among three cutaneous types of rosacea","volume":"62","author":"Kini","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15155-BIB0037|bjd15155-cit-0037","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/bmj.296.6634.1454","article-title":"Calculating confidence intervals for some non-parametric analyses","volume":"296","author":"Campbell","year":"1988","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1111\/bjd.15155-BIB0038|bjd15155-cit-0038","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"10.1111\/bjd.15155-BIB0039|bjd15155-cit-0039","first-page":"411","article-title":"Second-generation tetracyclines, a dermatologic overview: clinical uses and pharmacology","volume":"48","author":"Maibach","year":"1991","journal-title":"Cutis"},{"key":"10.1111\/bjd.15155-BIB0040|bjd15155-cit-0040","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2165\/00002018-199818060-00004","article-title":"Minocycline-induced pigmentation. Incidence, prevention and management","volume":"18","author":"Eisen","year":"1998","journal-title":"Drug Saf"},{"key":"10.1111\/bjd.15155-BIB0041|bjd15155-cit-0041","first-page":"644","article-title":"Drug-induced hyperpigmentation: a systematic review","volume":"11","author":"Krause","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1111\/bjd.15155-BIB0042|bjd15155-cit-0042","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/11319280-000000000-00000","article-title":"Minocycline in acne vulgaris: benefits and risks","volume":"11","author":"Ochsendorf","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"10.1111\/bjd.15155-BIB0043|bjd15155-cit-0043","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/1529-0131(199908)42:8<1691::AID-ANR18>3.0.CO;2-S","article-title":"Treatment of early seropositive rheumatoid arthritis with minocycline: four-year followup of a double-blind, placebo-controlled trial","volume":"42","author":"O'Dell","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1111\/bjd.15155-BIB0044|bjd15155-cit-0044","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1365-2133.2012.10845.x","article-title":"Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature","volume":"166","author":"Lebrun-Vignes","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15155-BIB0045|bjd15155-cit-0045","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","article-title":"Safety of doxycycline and minocycline: a systematic review","volume":"27","author":"Smith","year":"2005","journal-title":"Clin Ther"},{"key":"10.1111\/bjd.15155-BIB0046|bjd15155-cit-0046","first-page":"CD002086","article-title":"Minocycline for acne vulgaris: efficacy and safety","volume":"8","author":"Garner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/bjd.15155-BIB0047|bjd15155-cit-0047","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2133.2007.08056.x","article-title":"Association or lack of association between tetracycline class antibiotics used for acne vulgaris and lupus erythematosus","volume":"157","author":"Margolis","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.15155-BIB0048|bjd15155-cit-0048","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jaad.2015.02.1121","article-title":"Assessment of rosacea severity: a review of evaluation methods used in clinical trials","volume":"73","author":"Hopkinson","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.15155-BIB0049|bjd15155-cit-0049","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1179\/acb.2009.056","article-title":"Minocycline induced eosinophilic pneumonia: case report and review of literature","volume":"64","author":"Klerkx","year":"2009","journal-title":"Acta Clin Belg"},{"key":"10.1111\/bjd.15155-BIB0050|bjd15155-cit-0050","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/archderm.1996.03890320082013","article-title":"Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature","volume":"132","author":"Knowles","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.15155-BIB0051|bjd15155-cit-0051","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/archderm.1997.03890460044005","article-title":"Comparative safety of tetracycline, minocycline, and doxycycline","volume":"133","author":"Shapiro","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.15155-BIB0052|bjd15155-cit-0052","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/RHU.0b013e3180690693","article-title":"Minocycline-induced cutaneous polyarteritis nodosa","volume":"13","author":"Tehrani","year":"2007","journal-title":"J Clin Rheumatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.15155","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.15155\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:24:19Z","timestamp":1676384659000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/176\/6\/1465\/6687244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,8]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.15155","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5,8]]}}}